Perlecan deficiency causes endothelial dysfunction by reducing the expression of endothelial nitric oxide synthase

Physiological Reports

Volumn 3, Issue 1, 2015, Pages

  Nonaka, Risa ^a   Iesaki, Takafumi ^a   de Vega, Susana ^a   Daida, Hiroyuki ^a   Okada, Takao ^a   Sasaki, Takako ^b   Arikawa Hirasawa, Eri ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Endothelial cell; Nitric oxide synthase; Perlecan

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED RELAXING FACTOR; HEPARAN SULFATE; PERLECAN; SMALL INTERFERING RNA;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CHONDRODYSPLASIA; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

EID: 85006762254     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12272     Document Type: Article

References (41)

1. Arikawa-Hirasawa, E., H. Watanabe, H. Takami, J. R. Hassell, and Y. Yamada. 1999. Perlecan is essential for cartilage and cephalic development. Nat. Genet. 23:354-358.
2. Arikawa-Hirasawa, E., W. R. Wilcox, A. H. Le, N. Silverman, P. Govindraj, J. R. Hassell, et al. 2001. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat. Genet. 27:431-434.
3. Arikawa-Hirasawa, E., A. H. Le, I. Nishino, I. Nonaka, N. C. Ho, C. A. Francomano, et al. 2002. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am. J. Hum. Genet. 70:1368-1375.
4. Bonetti, P. O., S. H. Wilson, M. Rodriguez-Porcel, D. R. Jr Holmes, L. O. Lerman, and A. Lerman. 2002. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J. Am. Coll. Cardiol. 40:546-554.
5. Bouloumie, A., V. B. Schini-Kerth, and R. Busse. 1999. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc. Res. 41:773-780.
6. Braam, B., and M. C. Verhaar. 2007. Understanding eNOS for pharmacological modulation of endothelial function: a translational view. Curr. Pharm. Des. 13:1727-1740.
7. Cai, H., and D. G. Harrison. 2000. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87:840-844.
8. Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6:389-395.
9. Chatterjee, A., S. M. Black, and J. D. Catravas. 2008. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul. Pharmacol. 49:134-140.
10. Costell, M., K. Mann, Y. Yamada, and R. Timpl. 1997. Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides. Eur. J. Biochem. 243:115-121.
11. Costell, M., E. Gustafsson, A. Aszodi, M. Morgelin, W. Bloch, E. Hunziker, et al. 1999. Perlecan maintains the integrity of cartilage and some basement membranes. J. Cell Biol. 147:1109-1122.
12. Costell, M., R. Carmona, E. Gustafsson, M. Gonzalez-Iriarte, R. Fassler, and R. Munoz-Chapuli. 2002. Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice. Circ. Res. 91:158-164.
13. Goyal, A., N. Pal, M. Concannon, M. Paul, M. Doran, C. Poluzzi, et al. 2011. Endorepellin, the angiostatic module of perlecan, interacts with both the alpha2beta1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. J. Biol. Chem. 286:25947-25962.
14. Hozumi, K., N. Suzuki, P. K. Nielsen, M. Nomizu, and Y. Yamada. 2006. Laminin alpha1 chain LG4 module promotes cell attachment through syndecans and cell spreading through integrin alpha2beta1. J. Biol. Chem. 281:32929-32940.
15. Hummel, S., A. Osanger, T. M. Bajari, M. Balasubramani, W. Halfter, J. Nimpf, et al. 2004. Extracellular matrices of the avian ovarian follicle. Molecular characterization of chicken perlecan. J. Biol. Chem. 279:23486-23494.
16. Iesaki, T., S. A. Gupte, P. M. Kaminski, and M. S. Wolin. 1999. Inhibition of guanylate cyclase stimulation by NO and bovine arterial relaxation to peroxynitrite and H2O2. Am. J. Physiol. 277:H978-H985.
17. Inomata, T., N. Ebihara, T. Funaki, A. Matsuda, Y. Watanabe, L. Ning, et al. 2012. Perlecan-deficient mutation impairs corneal epithelial structure. Invest. Ophthalmol. Vis. Sci. 53:1277-1284.
18. Iozzo, R. V. 2005. Basement membrane proteoglycans: from cellar to ceiling. Nat. Rev. Mol. Cell Biol. 6:646-656.
19. Iozzo, R. V., and J. D. San Antonio. 2001. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 108:349-355.
20. Ishijima, M., N. Suzuki, K. Hozumi, T. Matsunobu, K. Kosaki, H. Kaneko, et al. 2012. Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation. Matrix Biol. 31:234-245.
21. Jiang, X., and J. R. Couchman. 2003. Perlecan and tumor angiogenesis. J. Histochem. Cytochem. 51:1393-1410.
22. Kaneko, H., M. Ishijima, I. Futami, N. Tomikawa-Ichikawa, K. Kosaki, R. Sadatsuki, et al. 2013. Synovial perlecan is required for osteophyte formation in knee osteoarthritis. Matrix Biol. 32:178-187.
23. Kerever, A., J. Schnack, D. Vellinga, N. Ichikawa, C. Moon, E. Arikawa-Hirasawa, et al. 2007. Novel extracellular matrix structures in the neural stem cell niche capture the neurogenic factor fibroblast growth factor 2 from the extracellular milieu. Stem Cells 25:2146-2157.
24. Laufs, U., V. La Fata, J. Plutzky, and J. K. Liao. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135.
25. McQuillan, L. P., G. K. Leung, P. A. Marsden, S. K. Kostyk, and S. Kourembanas. 1994. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am. J. Physiol. 267:H1921-H1927.
26. Nicole, S., C. S. Davoine, H. Topaloglu, L. Cattolico, D. Barral, P. Beighton, et al. 2000. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat. Genet. 26:480-483.
27. Nishida, K., D. G. Harrison, J. P. Navas, A. A. Fisher, S. P. Dockery, M. Uematsu, et al. 1992. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J. Clin. Invest. 90:2092-2096.
28. Noonan, D. M., A. Fulle, P. Valente, S. Cai, E. Horigan, M. Sasaki, et al. 1991. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J. Biol. Chem. 266:22939-22947.
29. Papapetropoulos, A., R. D. Rudic, and W. C. Sessa. 1999. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc. Res. 43:509-520.
30. Pillarisetti, S. 2000. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc. Med. 10:60-65.
31. Segev, A., N. Nili, and B. H. Strauss. 2004. The role of perlecan in arterial injury and angiogenesis. Cardiovasc. Res. 63:603-610.
32. Sessa, W. C., K. Pritchard, N. Seyedi, J. Wang, and T. H. Hintze. 1994. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ. Res. 74:349-353.
33. Stum, M., C. S. Davoine, S. Vicart, L. Guillot-Noel, H. Topaloglu, F. J. Carod-Artal, et al. 2006. Spectrum of HSPG2 (Perlecan) mutations in patients with Schwartz-Jampel syndrome. Hum. Mutat. 27:1082-1091.
34. Sumiyoshi, K., H. Mokuno, T. Iesaki, K. Shimada, T. Miyazaki, A. Kume, et al. 2008. Deletion of the Fc receptors gamma chain preserves endothelial function affected by hypercholesterolaemia in mice fed on a high-fat diet. Cardiovasc. Res. 80:463-470.
35. Tran-Lundmark, K., P. K. Tran, G. Paulsson-Berne, V. Friden, R. Soininen, K. Tryggvason, et al. 2008. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ. Res. 103:43-52.
36. Tsumaki, N., K. Tanaka, E. Arikawa-Hirasawa, T. Nakase, T. Kimura, J. T. Thomas, et al. 1999. Role of CDMP-1 in skeletal morphogenesis: promotion of mesenchymal cell recruitment and chondrocyte differentiation. J. Cell Biol. 144:161-173.
37. Vanhoutte, P. M. 2009. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ. J. 73:595-601.
38. Vikramadithyan, R. K., Y. Kako, G. Chen, Y. Hu, E. Arikawa-Hirasawa, Y. Yamada, et al. 2004. Atherosclerosis in perlecan heterozygous mice. J. Lipid Res. 45:1806-1812.
39. Xu, Z., N. Ichikawa, K. Kosaki, Y. Yamada, T. Sasaki, L. Y. Sakai, et al. 2010. Perlecan deficiency causes muscle hypertrophy, a decrease in myostatin expression, and changes in muscle fiber composition. Matrix Biol. 29:461-470.
40. Zembowicz, A., J. L. Tang, and K. K. Wu. 1995. Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J. Biol. Chem. 270:17006-17010.
41. Zoeller, J. J., J. M. Whitelock, and R. V. Iozzo. 2009. Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol. 28:284-291.